RBC Capital Reiterates Outperform on Mind Medicine, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Mind Medicine (NASDAQ:MNMD) and maintained a price target of $22.
June 05, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Mind Medicine (NASDAQ:MNMD) and maintained a price target of $22, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and a maintained price target of $22 by RBC Capital suggests strong confidence in Mind Medicine's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100